incyte.com - מחיר ריאלי לרכישת החברה במלואה INCY

This price chart on GURU.Markets illustrating value trends shows that the Enterprise Value of Incyte Corporation (INCY) is 19137.09. The business relies on stable therapeutic series and expansion within the dermatology segment for patients with rare skin pathologies. However, fierce competition and colossal R&D costs limit the number of market participants. The primary risks are associated with dependence on a single product and the potential expiration of patents.

Enterprise value combines market capitalization and net debt, reflecting the actual cost of a full business buyout accounting for all liabilities and liquid assets. For Incyte Corporation (INCY), which is actively integrating new oncology molecules and licenses, this metric serves as an indicator of expansion efficiency, allowing for the tracking of fundamental stability through a comprehensive operational valuation of the company.